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Abstract
Prion diseases currently have no effective therapy. These illnesses affect both animal and human populations, and are
characterized by the conformational change of a normal self protein PrP
C (C for cellular) to a pathological and infectious
conformer, PrP
Sc (Sc for scrapie). We used a well characterized tissue culture model of prion infection, where mouse
neuroblastoma cells (N2a) were infected with 22L PrP
Sc, to screen compounds for anti-prion activity. In a prior study we
designed a library of styryl based, potential imaging compounds which were selected for high affinity binding to
Alzheimer’s disease b-amyloid plaques and good blood-brain barrier permeability. In the current study we screened this
library for activity in the N2a/22L tissue culture system. We also tested the anti-prion activity of two clinically used drugs,
trimipramine and fluphenazine, in the N2a/22L system. These were selected based on their structural similarity to
quinacrine, which was previously reported to have anti-prion activity. All the compounds were also screened for toxicity in
tissue culture and their ability to disaggregate amyloid fibrils composed of PrP and b-amyloid synthetic peptides in vitro.
Two of the imaging agents, 23I and 59, were found to be both effective at inhibiting prion infection in N2a/22L tissue
culture and to be non-toxic. These two compounds, as well as trimipramine and fluphenazine were evaluated in vivo using
wild-type CD-1 mice infected peripherally with 139A PrP
Sc. All four agents significantly prolonged the asymptomatic
incubation period of prion infection (p,0.0001 log-rank test), as well as significantly reducing the degree of spongiform
change, astrocytosis and PrP
Sc levels in the brains of treated mice. These four compounds can be considered, with further
development, as candidates for prion therapy.
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Introduction
Prion diseases are conformational neurodegenerative disorders
characterized by the structural modification of the normal prion
protein, PrP
C(C for cellular), into a pathological conformer, PrP
Sc
(Sc for scrapie) [1,2]. They are a unique category of illness in that
they can be inherited, infectious or sporadic in occurrence. The
human forms of prionoses include kuru, Creutzfeldt-Jakob disease
(CJD), Gerstmann-Stra ¨ussler-Scheinker disease (GSS), fatal famil-
ial insomnia, sporadic fatal insomnia and the more recently
described ‘‘protease-sensitive prionopathy’’ [3–5]. In animals these
diseases include bovine spongiform encephalopathy (BSE) in
cattle, scrapie in sheep and goats, chronic wasting disease (CWD)
in deer and elk and transmissible mink encephalopathy (TME)
[3,4]. Currently there is no effective therapy for this group of
diseases [2,6–9]. The outbreak of bovine spongiform encephalop-
athy (BSE) and the resulting emergence of a new human prion
disease vCJD, highlight the public health threat from prion
diseases. In North America an ongoing threat from prion disease is
from chronic wasting disease (CWD). High rates of infection
among deer and elk populations have been reported, with
experimental data indicating that this disease is transmissible to
primates [10–12]. Hence there is a great need for effective
therapeutic approaches for prion disease.
Numerous studies have tried to develop anti-prion therapies,
typically utilizing prion infected cell lines where agents that
decrease PrP
Sc levels can be identified. These have included
diverse agents such as quinacrine, chlorpromazine, pentosan
polysulfate, Congo red, tetracycline and dendritic polyamines
[6,8]. Various immunotherapeutic approaches have also been
attempted [2]. Very few of these have been shown to be effective
in vivo using animal models of prion scrapie infection and none
have been shown to have a clinical effect in humans [6,8]. A
number of compounds which are amyloidophilic, such as Congo
red derivates, have been shown to have some anti-prion
effectiveness [13–16]. In addition compounds with a similar
scaffold structure to quinacrine and chlorpromazine have been
shown to have effectiveness in prion tissue culture [17,18].
Important properties for potential anti-prion agents with in vivo
effectiveness include the abilities to inhibit the prion replication in
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C to PrP
Sc interaction and to have high
blood brain barrier (BBB) permeability [8]. In prior studies we
designed a library of styryl based compounds which were selected
for high affinity binding to b-amyloid plaques and likely good BBB
permeability by virtue of having no charged moieties [19]. In the
present study we screened this library for inhibition of prion
infection using a N2a/22L tissue culture model [20,21]. In
addition we screened the effectiveness of fluphenazine and
trimipramine, which are a phenothiazine and a tricyclic
antidepressant, respectively, that are structurally similar to other
anti-prion agents such as quinacrine and are known to be BBB
permeable, as well as, being well tolerated in patients. All
compounds with effectiveness in N2a/22L prion infection were
screened for toxicity and their ability to inhibit both PrP and Ab
fibril formation in vitro. Effective and non-toxic compounds were
then tested in vivo using CD-1 mice infected with 139A PrP
Sc.
Results
Treatment of N2a/22L cells with compounds
N2a/22L cells at passage 5 and above were treated with a
library of 68 imaging compounds originally synthesized to bind to
and detect amyloid-b fibrils in vivo in an initial screen [19]. Of
these compounds, only 16, 23I, 26, 27, 52, 59, 63, 67, 69 and 84
showed anti-prion activity. However, only two compounds (#23I
and #59) consistently lowered PrP
Sc levels in infected cells
(Figure 1) with no apparent toxicity as judged by the MTS assay
(Figure 2). All the other imaging compounds with anti-prion
activity were found to be toxic (data not shown). Fluphenazine and
trimipramine were chosen for their tricyclic scaffold and aliphatic
side-chain, a structure previously found to be important for anti-
prion activity (Figures 3 and 4) [17]. The resulting half maximal
inhibitory concentration (IC50) for fluphenazine was 0.7296 mM
and 1.289 mM for trimipramine. The two imaging compounds
had higher IC50 values of 18.01 mM for #23I and 17.03 mM for
#59 (Figure 5).
Cytotoxicity Assay
Cytotoxicity, as determined by MTS colorimetric solution,
showed no significant cell death in either #23I or #59 at 5, 10 or
20 mM when applied to N2a/22l for 72 hours. Trimipramine was
nontoxic at 0.1, 1, and 10 mM. Fluphenazine showed no
significant difference in cell viability at 0.1 or 1 mM, but was
toxic at a 10 mM concentration. However, the effective anti-prion
dose of fluphenazine was much lower with complete abrogation at
less than 1 mM (Figure 2).
Survival of Mice
Treatment of mice with each compound began immediately
following peripheral inoculation with 139A PrP
Sc. Beginning at 90
days post inoculation with 139A, animals were tested weekly for
signs of ataxia, the equivalent of clinical onset and neuroinvasion
of prion disease. After 3 weeks of positive scoring by a blinded
observer, animals were sacrificed and the date post inoculation of
sacrifice recorded and plotted. The Kaplan-Meier survival curve
showed significant effects for all treatment groups. Survival
analysis by log-rank (Mantel-Cox) test gave a p=0.0005 for
fluphenazine, p=0.0001 for trimipramine, p,0.0001 for #23I,
and p,0.0001 for #59 (GraphPad Prism version 5.04). The
median survival for treatment groups were 205 dpi for fluphen-
azine, 210 dpi for trimipramine, 202 dpi for #23I, 215 dpi for
#59 compared to 170 dpi for control. This represents a
prolongation of the asymptomatic incubation of 21%, 24%, 19%
and 26% for fluphenazine, trimipramine, 23I and 59 compared to
controls, respectively. One animal from the trimipramine
treatment group remained healthy through 400 dpi, showing no
signs of cerebellar ataxia (Figure 6).
PrP
Sc in Spleen
Spleens were homogenized in PBS without Ca
++ or Mg
++ and
were subjected to sodium phosphotungstic acid precipitation to
amplify PrP
Sc levels. PrP
Sc levels in spleen homogenates averaged
95.8%, 98.6%, 116.3%, 73.8% and 82.1% for fluphenazine,
trimipramine, #23I, #59 and vehicle groups respectively (n=10).
Percent PrP
Sc was quantified compared to one previous 139A
infected animal which was considered 100% infectivity. The
difference in PrP
Sc levels between groups was not significant by
one-way ANOVA (Figure 7).
PrP
Sc in Brain homogenate
Brain homogenates of all sacrificed animals were subjected to
proteinase K digestion and resulting Western blot analysis of PrP
Sc
showed lower levels of PK-resistant material in brain homogenate
for all treatment groups compared to control (p,0.05 by one-way
ANOVA) (Figure 8). There was no detectable PrP
Sc by Western
blot in the brain of the one surviving trimipramine treated mouse
sacrificed at day 400 (data not shown).
Spongiform Density and Astrogliosis
The density of spongiform change and astrogliosis was
quantified in the basal ganglia of all animals in tissue stained with
cresyl violet and anti-GFAP antibody, respectively. Spongiform
change was expressed as the percent area of vacuoles in the fixed
sampling grid. The differences in spongiform density was
significant for all treatment groups versus control by One-way
ANOVA with a Newman-Keuls post hoc analysis, p,0.0001
(Figure 9). Astrogliosis was quantified as the percent area of
GFAP immunoreactive astrocytes in the fixed sampling grid
(Figure 10). The differences in GFAP immunoreactivity was
significant for all treatment groups versus control by One-way
ANOVA, p=0.0073.
Western Blot Detection and Quantification of PrP
C
Semiquantitative analysis for areas under the curves represent-
ing di-, mono-, and non-glycosylated bands of PrP
C were similar in
the treated and control mice. Two-way ANOVA analysis showed
no significant differences between control mice and trimipramine,




Compounds incubated with aggregated PrP 106-126 or Ab42
fibrils were measured for fluorescence intensity after 72 hours
(Figure 11). Subtracting peptide/Tris as background, fluorescence
intensity of compound/peptide/Tris/ThT mixtures were com-
pared to peptide/Tris/ThT as control. Compounds fluphenazine,
trimipramine, #23I, and #59 significantly lowered fluorescence
intensity in PrP 106-126 aggregates compared to control by
Student’s t-test, two tailed; p,0.0001 (Figure 11A). Controls (#8F
and buffer) did not show significant differences. Compounds also
significantly lowered fluorescence intensity in Ab42 fibrils;
p,0.0001 for fluphenazine, trimipramine, and #23I; p=0.0139
for #59; Student’s t-test, two-tailed (Figure 11B). The buffer
control did not show significant difference with Ab42 fibrils while
control 8F showed a significant increase (p,0.01) in fluorescence,
indicating it promoted further fibril formation.
Potential Anti-Prion Agents
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We demonstrate the in vivo effectiveness of four compounds for
prion infection using 139A PrP
Sc in CD-1 wild-type mice. All four
compounds were able to significantly prolong the asymptomatic
incubation period in peripherally infected mice, as determined by
a delay in the presentation of clinical symptoms. In addition,
treatment with the compounds reduced the levels of brain PrP
Sc,
as well as, the degree of spongiform change significantly. Hence
these compounds not only delayed neuroinvasion but also altered
its effectiveness and subsequent severity of brain pathology.
Animals were required to be sacrificed three weeks after the onset
of clinical symptoms due to humanitarian considerations and
IACUC regulations; therefore, we were unable to quantitate
whether or not treatment could have prolonged the symptomatic
period beyond three weeks. However, we demonstrated that
treatment does reduce the severity of disease by showing
reductions in the degree of spongiform change and GFAP
immunoreactivity, as well as lower levels of PrP
Sc in the brains
of all the treated groups. These compounds were not toxic in tissue
culture using a standard MTS assay with doses used in the current
experiment and in the case of fluphenazine and trimipramine
utilized clinically. Furthermore, the treated mice showed no signs
of toxicity with any of the compounds. The mechanism of action
of these compounds is likely, at least in part, related to their ability
to hinder the PrP
C to PrP
Sc interaction. Our evidence for this is
that each of the tested compounds is able to disaggregate both Ab
and PrP amyloid fibrils in vitro. A precise understanding of the
molecular mechanisms and pathways involved in the PrP
C to
PrP
Sc conversion remains to be elucidated; however, there is
abundant evidence of the primal importance of ‘‘seeding’’ by
aggregated PrP
Sc molecules acting as template for PrP
C binding
and subsequent conversion to more PrP
Sc [22]. This interaction is
critically dependent on the correct stereochemistry as supported by
the existence of a species barrier for prion infection, related to
minor differences in the primary sequence of PrP
C in different
species. It is not surprising that any compound that may alter or
mask the mutual conformational complementarity required in
prion propagation will be inhibitory. This likely represents a
mechanism of action of these compounds.
We chose to investigate the anti-prion activity of fluphenazine
and trimipramine, because of structural similarity to quinacrine, as
well as their known good BBB permeability and well characterized
clinical safety. Fluphenazine, an antipsychotic, is used in the
treatment of schizophrenia, hallucinations, delusions and acute
mania. Trimipramine is a tricyclic antidepressant. Quinacrine has
been shown to be highly effective at clearing prion infection in
tissue culture [17,23]. However, this result contrasted with in vivo
Figure 1. Anti-Prion Activity of Styryl-based Compounds 23I and 59 Styryl-based compounds. A,B) #23I and C,D) #59 were applied to
N2a/22L for 72 hrs at 0.5, 1.0, 2.5, 5, 10, and 20 mM. A,C) Blots represent proteinase-K digested cell lysates detected with 6D11 anti-PrP monoclonal
antibody. Bands respresent di-, mono-, and non-glycosylated isoforms at approximately 28, 23 and 17 kDa respectively. B,D) Bar graph
representations of percent PrP
Sc infectivity compared to non-treated control (N2a/22L). B) #23I reduced PrP
Sc levels by 98.4%, 88.1%, 86.5%, 73.5%,
67.2% and 56.4%. D) #59 reduced PrP
Sc levels by 96.8%, 92.4%, 85.4%, 79.5%, 73.9% and 54.0%. Differences are significant by One-way ANOVA
(**p=0.0011), and *p,0.05 Newman-Keuls post-hoc analysis versus N2a/22L as indicated on the graph.
doi:10.1371/journal.pone.0024844.g001
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models [24,25]. One study dosed mice peripherally infected with
2% (w/v) of 6PB1 mouse- adapted BSE brain homogenate with
10 mg/kg quinacrine for three weeks. Treated mice showed no
clinical improvements or increase in survival time compared to
non-treated controls [24]. When quinacrine was tried in humans
with Creutzfeldt-Jakob disease, no therapeutic effectiveness was
demonstrated, despite the use of high doses [26]. Contrasting with
this lack of success of quinacrine treatments in vivo, we show both
fluphenazine and trimipramine to have good anti-prion therapeu-
tic activity in vivo using a mouse model, opening up the possibility
of clinical assessments of efficacy.
A number of amyloidophilic compounds have been reported to
have anti-prion activity. It was initially shown that Congo red, a
standard histological dye used to label amyloid deposits, has anti-
prion activity in an in vivo model [27]. However, due to its
benzidine structure, Congo red is carcinogenic and toxic, making
it unsuitable for animal or human use. We and another group
have developed Congo red analogs that have effectiveness in tissue
culture, but in vivo effectiveness was much more limited [13,15].
The Doh-ura group have tested a number of PrP amyloid imaging
ligands for anti-prion clearance in cell culture and shown some
effectiveness in vivo using Tg20 PrP over-expressing transgenic
mice [14,16]. However, in Tg7 mice and wild type hamsters
inoculated with 263K PrP
Sc, there was no significant prolongation
of the incubation period. We describe the effectiveness of two
chemically distinct compounds, which were initially developed as
amyloid-b imaging agents, as having anti-prion activity both in a
cell culture model, as well as, in vivo using wild-type CD-1 mice.
These compounds, 59 and 23I, have no toxicity in a standard
MTT assay or apparent toxicity in vivo. This raises the possibility
that they might serve as lead compounds with anti-prion activity.
The mechanism of action of our two compounds, similar to other
amyloidophilic agents, is likely the inhibition of the PrP
C to PrP
Sc
interaction, consistent with our finding that both compounds are
able to disaggregate pre-formed PrP 106-126 fibrils.
In summary, we demonstrate the in vivo effectiveness of four
compounds for peripheral prion infection. Two of these com-
pounds, trimipramine and fluphenazine, are widely used in humans
for other indications and are both BBB permeable and very safe.
This opens the possibility of clinical evaluation of these compounds
for anti-prion activity. We also have identified two amyloidophilic
compounds with anti-prion activity from a library originally
designed for high affinity binding to Ab plaques and BBB
permeability, which can serve as lead compounds for the design
of even more effective drugs. These agents are now being further
tested in other in vivo prion models, as well as for therapeutic
effectiveness when applied closer to the onset of clinical symptoms.
Materials and Methods
Tissue Culture Model of Prion Disease
N2a mouse neuroblastoma cells (ATCC line CCL-131) were
maintained in minimal essential medium (MEM) supplemented
with heat-inactivated 10% fetal bovine serum, penicillin (100
units/ml) and streptomycin (100 mg/ml) at 37uCi n5 %C O 2.
Brains of terminally ill CD-1 mice infected with mouse-adapted
22L prion strain were homogenized (10% w/v) in cold phosphate-
Figure 2. Cytotoxicity Assay. Cytotoxicity of compounds. A) Fluphenazine B) trimipramine C) #23I and D) #59 were applied to N2a/22L cells for
72 hours. Cells were then transferred to 96 well plates and allowed to attach overnight. The MTS colorimetric solution was added and allowed to
incubate for 2–3 hours before reading absorbance at 490 nm. Graphs are plotted as percent cell survival compared to non-treated control. Only
fluphenazine at 10 mM concentration was significantly toxic; ***p,0.0001, Student’s t-test, two-tailed.
doi:10.1371/journal.pone.0024844.g002
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to N2a/22L for 72 hrs at 0.1, 0.5, 1.0 and 2.5 mM. B) Western blot of PK-digested cell lysates. C) Bar graph representation of PrP
Sc reduction.
Fluphenazine reduces PrP
Sc infectivity by 84.8%, 75.5%, 24.0% and 2.9% respectively. Differences are significant by One-way ANOVA (***p,0.0001),
and *p,0.05 Newman-Keuls post-hoc analysis versus N2a/22L as indicated on the graph.
doi:10.1371/journal.pone.0024844.g003
Figure 4. Structure and Anti-Prion Activity of Trimipramine. Trimipramine. A) Shows the structure of trimipramine. Trimipramine was applied
to N2a/22L for 72 hrs at 0.1, 0.5, 1.0, 2.5 and 5 mM. B) Western blot of PK-digested cell lysates. C) Bar graph representation of PrP
Sc reduction.
Trimipramine reduces PrP
Sc infectivity by 89.6%, 77.7%, 68.2%, 22.7% and 5.6% respectively. Differences are significant by One-way ANOVA
(***p,0.0001), and *p,0.05 Newman-Keuls post-hoc analysis versus N2a/22L as indicated on the graph.
doi:10.1371/journal.pone.0024844.g004
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previously described [20,21]. For infection of N2a cells, the
homogenate was further diluted to 2% in Opti-MEM and added
to confluent 12.5 cm
2 flasks (Falcon). After 4–5 hours, an equal
volume of regular MEM was added and cells were incubated in
the presence of infectious brain homogenate overnight. The cells
were then washed twice with PBS and fresh MEM was replaced.
Cells were grown until confluence and then split into 1:4 dilutions
and transferred to 25-cm
2 flasks until the fourth passage when
traces of 22L brain homogenate can no longer be detected.
Figure 5. Inhibitory Concentrations (IC50) for Fluphenazine, 23I, Trimipramine and 59 Half-maximal inhibitory concentrations (IC50)
for A) fluphenazine B) #23I C) trimipramine and D) #59. Graphs were plotted as percent inhibition of PrP
Sc infectivity versus log of dose. IC50
values are 0.7296 mM for fluphenazine, 1.289 mM for trimipramine, 18.01 mM for #23I and 17.03 mM for #59.
doi:10.1371/journal.pone.0024844.g005
Figure 6. Kaplan-Meier Survival Curve. Survival analysis. The
Kaplan-Meier survival curve shows significant treatment effects for all
treatment groups. Survival analysis by log-rank test gave p values of:
p=0.0005 for fluphenazine, p=0.0001 for trimipramine, p,0.0001 for
#23I, and p,0.0001 for #59. The median survival for treatment groups
were 205 dpi for fluphenazine, 210 dpi for trimipramine, 202 dpi for
#23I, 215 dpi for #59 compared to 170 dpi for control. One animal in
the trimipramine group remained clinically asymptomatic at 400 dpi,
when it was sacrificed.
doi:10.1371/journal.pone.0024844.g006
Figure 7. Level of PrP
Sc in the Spleen. PrP
Sc level in the spleen at
60 dpi. At this time, there is peripheral replication of PrP
Sc but CNS
invasion has not yet occurred. Spleen homogenates for each group
(n=10) were tested for levels of PrP
Sc and plotted with the vehicle level
represented as 100% infectivity. Differences between each treated
group versus the control group were not significant.
doi:10.1371/journal.pone.0024844.g007
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N2a/22L cells (from the fifth passage after infection and above)
were plated in six-well plates. Fluphenazine and trimipramine
were applied at concentrations ranging from 0.1–5 mM for
72 hours, while each of the library of 76 amyloid imaging
compounds were applied at 1–20 mM for 72 h (see Figure S1
showing the structure of each of the 76 compounds which were
screened). A fresh treatment was applied daily until lysis. The level
of PK-resistant PrP
Sc was measured by Western blot. Each
experiment included both a positive control (non-treated N2a/22L
cells) and a negative control (non-infected N2a cells). Quinacrine
was applied at a concentration of 1.5 mM for 72 h as a treatment
positive control. The levels of PrP
Sc was expressed as percentages
of the average value from a positive control (nontreated N2a/22L
cells), while the optic density of the background was taken from
negative control lanes (N2a cells). Half maximal inhibitory
concentration (IC50) values were calculated by plotting percent
of PrP
Sc reduction versus log of dose.
Detection and quantification of PrP
Sc in N2a/22L cells
Cells were harvested using ice-cold lysis buffer [NaCl, 150 mM;
triton X-100, 0.5%; sodium deoxycholate, 0.5%; and Tris-HCl,
50 mM, pH 7.5; with a protease inhibitor cocktail (Roche,
Indianaplis, IN, USA)], as previously described [20,21]. The lysates
were centrifuged for 3 minutes at 10,000 g to remove cell debris
and the total protein concentration was measured in the
supernatant using the bicinchoninic acid assay (BCA; Pierce,
Rockford, IL, USA). Aliquots containing 200 mg of total protein
were titrated by adding buffer to achieve a final protein
concentration of 1 mg/ml. Samples were digested with proteinase
K (PK; Roche) for 30 min at 37uC. The enzyme-to-protein weight
ratio was 1:50. PK activity was quenched by adding phenylmetha-
nesulphonyl fluoride to achieve a final concentration of 3 mM.
Samples were then centrifuged at 20,000 g for 45 min at 4uC.
Pellets were resuspended in PBS and tricine sample buffer (Bio-rad,
Hercules, CA, USA) with b-mercaptoethanol (BME), boiled at
95uC for 5 min and then subjected to electrophoresis on 12.5%
SDS-polyacrylamide Tris-tricine gels. Following overnight electro-
phoresis the proteins were transferred onto nitrocellulose mem-
branes (Amersham Biosciences, Piscataway, NJ, USA) for 1 hour at
400 mA ˚ using CAPS buffer (3-cyclohexylamino-1-propanesulpho-
nic acid) containing 10% methanol. The membranes were blocked
with 5% Carnation nonfat milk in TBST (Tris, 10 mM; NaCl,
150 mM; Tween 20, 0.1%, pH 7.5) for 1 h at room temperature
and then incubated with anti-PrP Mab 6D11 dilutedto 1:3000[28].
Following extensive washing in TBST the membranes were
incubated with a horseradish-peroxidase conjugated goat anti-
mouse antibody (Thermo Scientific, Rockford, IL, USA) and then
developed using an enhanced chemiluminescent substrate (ECL
Western Blotting Substrate; Pierce). Membranes were applied to
autoradiography film (Super RX Fuji Medical XRay Film; Fujifilm,
Tokyo, Japan). Developed films were converted into 8-bit grayscale
digital files using an Epson Perfection 1200 U scanner (Epson
America, Long Beach, CA, USA) and Adobe Photoshop software
(Adobe Systems, San Jose, CA, USA) and saved in JPEG format
with a resolution of 600 dpi. Quantification of PrP
Sc was performed
by densitometric analysis using NIH Image J software. Areas under
the curves for the three PrP bands representing non-, mono-, and
diglycosylated isoforms of the protein were summarized from each
sample to calculate total PrP
Sc level.
Cytotoxicity Assay
Compounds used to treat N2a/22L cells were assessed for
cytotoxicity by CellTiter 96 AQueoue Non-Radioactive Cell
Proliferation Assay (Promega, Madison, WI). Treated cells were
plated onto 96-well plates in triplicate and allowed to attach
overnight. The MTS colorimetric solution [3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazoli-
um] was then added and allowed to incubate at 37uC for 2–
3 hours. MTS is bioreduced by cells into a formazan product that
is soluble in tissue culture medium. The absorbance of the
formazan at 490 nm was measured directly from 96-well plates in
a Spectra max M2 and using SoftMaxPro software Version 4.8.
Viability was determined as percent of control, with control being
non-treated cells. Statistical significance of compound toxicity was
analyzed by Student’s t-test, two-tailed (GraphPad Prism, version
5.04; GraphPad Inc., San Diego, CA, USA).
Treatment in Animal Models
Ethics Statement. Animalstudieswereapprovedbythe NYU
School of Medicine Institutional Animal Care and Use Committee
(IACUC, protocol 090201-02) and were consistent with the
recommendations of the American Veterinary Association.
Figure 8. Level of PrP
Sc in the Brain. Brain homogenates of clinically symptomatic animals were PK-digested to assess PrP
Sc levels. A) Shows a
Western blot of a representative single mouse from each treatment group. B) Bar graph representation of total group brain homogenate PrP
Sc levels
as measured by O.D. of Western blots. The vehicle group is set as 100%. The mean values as a percentage of the vehicle control group are 68%, 83%,
80% and 85% for the fluphenazine, trimipramine, 23I and 59 groups, respectively. (p,0.05 by one-way ANOVA). Compared to vehicle control p=0.01
for fluphenazine, p=0.02 for trimipramine, p=.002 for 23I and p=0.02 for 59 (by two-tailed t test).
doi:10.1371/journal.pone.0024844.g008
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Female CD-1 mice, aged 2 months, were inoculated by a single
intraperitoneal (i.p.) injection of 100 ml of 1% brain homogenate
from terminally ill 139A scrapie-infected mice. A single batch of
139A inoculum prepared from a number of pooled brains
harvested under sterile conditions was used to inoculate mice.
Treatment protocol
Fluphenazine-dihydrochloride (Sigma-Aldrich, St. Louis, MO,
USA) was intraperitoneally (i.p.) administered daily at 1 mg/kg.
Trimipramine maleate salt (Sigma-Aldrich), and the imaging
compounds (#23I, #59) were administered i.p. at 10 mg/kg. The
doses of fluphenazine and trimipramine were comparable to
normal human usage, while doses of the imaging compounds were
based on the highest tolerated dose of quinacrine in animal models
[17]. Animals were treated immediately after inoculation with
139A brain homogenate, and 5 times a week thereafter. Due to the
unknown long-term potential toxic side effects of the imaging
compounds, the #23I and #59 groups were treated for 1 month
following the 139A challenge while the groups given fluphenazine
and trimipramine (which are known to be non-toxic) were
continually treated until sacrifice. Treatment groups consisted of
25 mice each with the control group of 25 mice given sterile
phosphate-buffered saline. A cohort of 10 animals per treatment
and control groups was sacrificed at 60 days to analyze peripheral
PrP
Sc replication. Beginning at 90 days post inoculation (dpi) and
weekly thereafter, the 15 remaining animals per group underwent
a test for ataxia in traversing parallel bars.
Assessment of disease
The parallel bar apparatus contains a series of parallel bars 3 mm
in diameter placed 7 mm apart. Animals were scored based on their
Figure 9. Quantitation of Spongiform Change. Spongiform density. Spongiform change in the basal ganglia of all groups were quantified using
Bioquant NovaPrime image analysis. Histological sections were stained with cresyl violet. A,B) Represent a section of basal ganglia of non-treated
control animals at 256 and 1006 magnification respectively. C,D) Represent a treatment group (fluphenazine) at 256 and 1006 magnification.
Arrows are highlighting vacuoles representing spongiform change. E) Bar graph representation of spongiform density quantification of all animal
groups. Graphs were plotted as percent spongiform change per area. All treatment groups had significantly lower levels of spongiform density
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in a row, indicating early signs of clinical symptoms as previously
reported [20,29]. The observer was blinded to the treatment status
of the mice. The earliest detectable clinical symptoms of central
nervous system involvement include an impaired activity level and
competency when attempting to cross the parallel bars. Symptom-
atic animals were euthanized with an i.p. injection of ketamine/
xylazine 100/10 mg/kg and the clinical diagnosis was confirmed by
demonstration of PrP
Sc on Western blots from PK-digested brain
homogenate. The Kaplan and Meier survival curves of the treated
and control animals were analyzed by the log-rank test (GraphPad
Prism, version 5.04, GraphPad Software Inc.).
Analysis of disease
Animals were sacrificed and perfused with heparinized PBS.
The tissues collected were the brain, spleen, Peyer’s patches and
mesenteric lymph nodes. The brain was divided along the
longitudinal fissure with the right brain hemisphere (including
cerebellum and brain stem) fixed in periodate-lysine-paraformal-
dehyde (PLP) and the left hemisphere snap-frozen and homoge-
nized for biochemical analysis. Samples designated for biochem-
ical analysis were weighed and homogenized (10% w/v) in
Dulbecco’s phosphate-buffered saline (DPBS). Homogenates were
divided in 150 ml aliquots, flash frozen and stored at 280uC until
analysis. Tissue homogenates underwent sodium phosphotungstic
acid precipitation to amplify PrP
Sc levels in brain and lymphoid
tissue. Tissue homogenates were centrifuged at 806g for 1 minute
to remove gross cellular debris. Aliquots of the supernatant were
mixed with an equal volume of 4% sodium lauroyl sarcosinate
(sarkosyl) (Sigma-Aldrich) then incubated for 10 min at 37uC with
constant agitation. Benzonase nuclease (Novagen, EMD Chemi-
cals, Gibbstown, NJ, USA) was added at a final concentration of
50 U/ml followed by 1 mM MgCl2, then incubation for 30 min at
37uC with constant agitation. Pre-warmed 4% sodium phospho-
tungstic acid/170 mM MgCl2 (pH 7.4) was added and the
solution incubated for 30 min at 37uC with constant agitation
Figure 10. GFAP Immunoreactivity as a Measure of Astrocytosis. Histological sections immunostained with anti-GFAP polyclonal antibody
were quantified using Bioquant NovaPrime image analysis. A,B) Histological representation of non-treated control animal at 256 and 1006
magnification, respectively (scale bars corresponding to 100 and 400 mm are shown). C,D) Shows representative sections from a treatment group
(#23I) at 256and 1006magnification. E) Shows a bar graph of the immunoreactivity quantitation for all groups. Graphs were plotted as percent
immunoreactivity per area. Differences were significant by One-way ANOVA; p=0.0073.
doi:10.1371/journal.pone.0024844.g010
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was resuspended in 0.1% sarkosyl. Samples were then PK-digested
as previously described for 1 hour at 37uC. Tricine sample buffer
with BME was added and samples boiled at 95uC for 5 min before
subjection to electrophoresis on 12.5% SDS-polyacrylamide Tris-
tricine gels. Following overnight electrophoresis the protein was
transferred onto nitrocellulose membranes and Western Blot for
PrP
Sc detection as previously described. Immersion-fixed samples
were stained with cresyl violet and immunolabeled with anti-PrP
mAb 6D11.
Quantification of Disease
The density of spongiform changes and astrogliosis were
quantified using Bioquant NovaPrime v. 6.95 image analysis
system (Bioquant, R&M Biometrics Inc., Nashville, TN) on
sections stained with cresyl violet and immunostained with
polyclonal anti-GFAP antibody (Dako, Denmark), respectively.
GFAP (glial fibrillary acidic protein) is the major intermediate
filament of astrocytes; it is used as a measure of astrocytosis and for
assessing the degree of prion infection as previously reported by us
and others [20,30]. Analysis includes several ROIs in the basal
ganglia for spongiform change and astrogliosis. The stereological
coordinates of ROI outlines were stored in Bioquant memory with
the system randomly superimposing a sampling grid
(8006800 mm) over the contours of the traced ROIs. The
rectangular test areas (6406480 mm) were placed by the program.
Western Blot Detection and Quantification of PrP
C
Brain samples were weighed, homogenized and sonicated (10%
w/v) in a buffer containing 20 mM Tris pH 7.5, 250 mM sucrose,
1 mM EDTA, 1 mM EGTA, and CompleteH protease inhibitor
(Boehringer-Mannheim, Indianapolis IN), as previously described
[31]. Samples were centrifuged for 3 min at 10,0006ga t4 uCt o
remove cellular debris. The total protein concentration was
assayed by the BCA method. If not used immediately, superna-
tants were divided into 100 ml aliquots, which were flash frozen
and stored at 280uC. Semi-quantitative Western-blot was used to
compare the relative content of PrP
C among samples containing
matched amounts of total protein. Aliquots of brain homogenates
containing 20 mg of the total proteins were titrated by adding
sample buffer to a final protein concentration of 1 mg/1 ml.
Samples were subjected to SDS-PAGE and Western-blotting into
nitrocellulose membranes where PrP
C was detected with Mab
6D11 (0.05 mg/ml) as described previously [20]. For the
densitometric analysis, the exposure time of Western blot
membranes was kept standard in all experiments at 30 seconds.
Developed films were converted into 8 bit grayscale digital files
using a Epson Perfection 4990 scanner (Epson America; Long
Beach, CA) and Adobe Photoshop software 7.01 (Adobe Systems;
San Jose, CA) and saved in a TIF format with a resolution of
600 dpi. Quantification of PrP
C was performed using NIH Image
J software v 1.34. Areas under the curves for three PrP
C bands
representing non-, mono-, and diglycosylated isoforms of the
protein were analyzed from each sample.
Preparation of Ab42/PrP 106-126 fibrils
Ab42 was monomerized by treatment with ice-cold 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP) (Sigma-Aldrich) to a final concen-
tration of 1 mM, as previously described [32]. The solution was
incubated at room temperature for 60 min, then placed on ice for
5–10 minutes. The solution was then aliquoted to 0.45 mg Ab42
into non-siliconized microfuge tubes and allowed to evaporate
overnight. All traces of HFIP were removed by speedvac if
necessary. The dried peptide films were stored at 280uC until
resuspension in dimethyl sulfoxide (Sigma-Aldrich) to a final
concentration of 5 mM Ab42. Fibrils were prepared by dilution in
10 mM HCl to a final concentration of 100 mM, vortexed for
15 seconds, followed by 24 hour incubation at 37uC. PrP 106-126
was dissolved in sterile PBS to a final concentration of 1 mM and
allowed to spontaneously aggregate at room temperature for 3–
5 hours.
Thioflavin T assay for a destabililzation effect on
preformed fibrils
The destabilization effect on preformed fibrils by the com-
pounds was measured by thioflavin T (Sigma-Aldrich) fluores-
cence, as previously described [32,33]. Compounds were incubat-
ed with either Ab42 fibrils or aggregated PrP 106-126 at a 1:2
peptide to compound molar ratio for 1 to 3 days. Controls
included the buffer solution for the compounds alone and
compound 8F. 8F was chosen at random as a representative
compound from among the library of 68 screened imaging
compounds which bound to Ab fibrils but did not show anti-prion
activity in tissue culture (see Figure S1 showing a list and structure
Figure 11. Disaggregation of Pre-formed PrP106-126 and Ab 42 Fibrils. Thioflavin T fluorescence of compounds incubated with A) PrP 106-
126 and B) Ab42 fibrils for 72 hours. Compounds incubated with both with PrP 106-126 and Ab42 significantly lowered fluorescence intensity.
p,0.0001 by One-way ANOVA; *p,0.05, **p,0.01, ***p,0.001 Newman-Keuls post-hoc analysis of compounds versus peptide control.
doi:10.1371/journal.pone.0024844.g011
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mixed in 50 mM Tris buffer (pH 7.4) to a final concentration of
5 mM then added to peptide/compound complexes. The fluores-
cence intensity of the peptide/compound/ThT/Tris complexes
were measured using an excitation wavelength of 440 nm and an
emission wavelength of 482 nm. Readings were taken every
20 seconds over a period of 5 minutes at time points ranging from
0 to 72 hrs. Statistical significance was measured by one-way
ANOVA (GraphPad Prism) with a Dunnett post hoc comparison
to peptide/ThT/Tris as the reference group.
Supporting Information
Figure S1 Names and Structures of the Amyloidophilic
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